linjc16/ctgov huggingface dataset:
The Evaluation of NETs, Caspase-1 and Cytokines in ARDS Patients

Study Overview
=================
Brief Summary
-----------------
enrollment criteria and clinical data collection: follow the principles of medical ethics, the development of inclusion and exclusion criteria, select 90 cases of ARDS patients, in the active treatment at the same time, according to the Berlin standard severity of the disease divided into mild group, moderate Group and severe group, according to the prognosis during hospitalization is divided into survival group and death group. BALF specimens were collected on the day of admission to detect the levels of NETs and alveolar macrophages. The acute and chronic health status scoring system Ⅱ (APACHEⅡ) and Murray acute lung injury score, blood routine, creatinine, urea nitrogen, fasting blood glucose, Item, mean arterial pressure, arterial blood gas analysis, oxygenation index; record the patient's mechanical ventilation time and other data; Pearson linear correlation analysis of BALF in the content of NETs, alveolar macrophage coke death level was a positive correlation between the Spearman rank correlation analysis BALF in the NETs content and alveolar macrophage coke death level, APACHE Ⅱ, Murray score, creatinine, Urea nitrogen, fasting blood glucose and other indicators and ARDS severity was positively correlated; To analyze the prognostic factors of different prognostic factors, to evaluate the content of NETs in BALF, the level of alveolar macrophage coke, APACHEⅡ and Murray scores were analyzed by receiver operator characteristic curve (ROC curve) Short - term survival outcome prognostic value.

Official Title
-----------------
IRF-1 Regulate Alveolar Macrophage Pyroptosis in Acute Lung Injury and of Which Will be Possible Mechanism

Conditions
-----------------
ARDS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ARDS patients diagnosis within 3 days Over 18 years old but no more than 75 years old Exclusion Criteria: Severe thoracic open trauma Pulmonary embolism Severe cardiovascular and cerebrovascular disease Endocrine system diseases Coagulation dysfunction Liver and kidney failure Malignant tumors Cardiogenic pulmonary edema

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neutrophil extracellular traps, caspase-1,cytokines measurement | Assessments with neutrophil extracellular traps be presented in ng/ml; Assessments with caspase-1 and cytokines be presented in pg/ml | 4 years |
Oxaliplatin in Rectal Cancer

Study Overview
=================
Brief Summary
-----------------
Phase I: To determine the maximum tolerated dose, and recommended dose of the proposed doses of oxaliplatin in this study Phase II: To determine the treatment efficacy according to response rates from phase I.

Official Title
-----------------
Phase I-II Study of Preoperative Oxaliplatin-FU and Radiotherapy for Patients With Rectal Cancer

Conditions
-----------------
Rectal Neoplasms

Intervention / Treatment
-----------------
* Drug: Oxaliplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional. Main criteria are listed hereafter: Inclusion Criteria: ECOG: 0-2 Histological proved rectal adenocarcinoma No chemotherapy treatment on the previous 6 months before inclusion. No previous pelvic radiotherapy treatment Exclusion Criteria: Important Biological abnormality (renal, hepatic and/or hematological) Intestinal occlusion or subocclusion Peripheral neuropathy Pregnant or breast-feeding women. Potential child-bearing women with a positive pregnancy test. Participation in other trials on the previous 4 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phase I : Maximum Tolerated Dose & Recommended Dose |  | Days 1, 15, 29 | 
| Phase II : Response and resectability rate. |  | 6 cycles in 6 months |
Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence

Study Overview
=================
Brief Summary
-----------------
To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive, Disease Exacerbation, Pulmonary Embolism, Prothrombin Fragments

Intervention / Treatment
-----------------
* Other: CT pulmonary angio, blood tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD exacerbation Able to give informed consent Able to perform spirometry Exclusion Criteria: Known malignancy Known hypercoagulable state Receiving anticoagulant treatment Pregnancy Renal failure Allergy to Iodine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD exacerbation<br>Patients admitted to hospital with COPD exacerbation | Other: CT pulmonary angio, blood tests<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD

Study Overview
=================
Brief Summary
-----------------
To investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia. To examine the association or effects of clinical and biochemical factors (lab results and medication, etc.) on serum levels of adipokines and hepatokines in certain subjects with non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.

Conditions
-----------------
Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, Metabolic Syndrome

Intervention / Treatment
-----------------
* Other: serum blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: dyslipidemia 1. serum triglyceride≥150mg/dl, or taking medication to lower triglyceride levels (e.g. fibrates, niacin, omega-3, etc.) or 2. serum LDL-C≥100mg/dl, or taking medication to lower LDL-C levels (e.g. statin, ezetimibe, etc.) type 2 diabetes 1. defined according to the ADA guideline (DM definition) or 2. taking any anti-diabetic medications non-alcoholic fatty liver disease (NAFLD) 1. diagnosed as having fatty liver by ultrasonogram or 2. diagnosed as having fatty liver by transient elastogram (Fibroscan) or 3. diagnosed as having fatty liver by abdomina CT scan Normal control 1. should not be included in other groups as above and 2. not taking any medication related to diabetes and dyslipidemia and 3. BMI <25kg/m2 Exclusion Criteria: subjects who refused to agree with informed consents subjects with organ-transplantation serum creatinine ≥1.5mg/dl pregnant women liver cancer or pancreatic cancer subjects with chronic hepatitis B or C virus infection for NAFLD group, subjects with excessive alcohol consumption (men: ≥210g of alcohol per week, women: ≥140g of alcohol per week)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1) Normal control<br>metabolically healthy with no obesity | Other: serum blood sampling<br> <br> |
| 2) dyslipidemia<br>high triglyceride levels or LDL-C levels | Other: serum blood sampling<br> <br> |
| 3) type 2 diabetes<br>defined in 'inclusion criteria' | Other: serum blood sampling<br> <br> |
| 4) non-alcoholic fatty liver disease<br>defined in 'inclusion criteria' | Other: serum blood sampling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| new adipokines | several candidate adipokines and hepatokines to predict diseases will be measured using ELISA | To 8h fasting blood sample | 
| new hepatokines | several candidate adipokines and hepatokines to predict diseases will be measured using ELISA | To 8h fasting blood sample |
Impact of Aminoglycosides in Hypotensive Septic Oncology Patients

Study Overview
=================
Brief Summary
-----------------
This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs. Prior research shows aminoglycosides antibiotics are frequently used to treat sepsis, but their clinical impact in hypotensive oncology patients upon the progression of sepsis is not known.

Detailed Description
-----------------
PRIMARY OBJECTIVE: I. To assess the impact of beta-lactam (BL) + aminoglycoside (AG) combination therapy in hypotensive septic oncology patients. OUTLINE: Patients' medical charts are reviewed retrospectively.

Official Title
-----------------
Evaluating the Impact of Aminoglycosides in Hypotensive Septic Oncology Patients

Conditions
-----------------
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Septicemia

Intervention / Treatment
-----------------
* Other: Electronic Health Record Review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (age >= 18 years) with a diagnosis of sepsis during the index hospital admission identified by International classification of diseases (ICD)-10 codes (as specified below) receiving BL antibiotics within 6 hours prior to or following the onset of hypotension To be included in the AG group, patients must have received at least 1 dose of intravenous (IV) tobramycin or amikacin in addition to the BL therapy within the above time period Exclusion Criteria: Age < 18 years Receipt of IV AG outside of the above time frame in the AG group or receipt of IV AG within 48 hours prior to or following the onset of hypotension in the BL backbone group Pregnancy Patients not receiving therapy with BL antibiotics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational (medical record review)<br>Patients' medical charts are reviewed retrospectively. | Other: Electronic Health Record Review<br>* Medical record reviewed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to resolution of hypotension | Defined as a mean arterial pressure > 65 mmHg not requiring vasopressors and sustained for >= 24 hours. | Within 7 days from hypotension onset |
NAVITAS and ENVISION

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to characterize the relationship between select objective metrics and clinical outcomes in chronic pain patients treated with Boston Scientific commercially approved neurostimulation systems.

Official Title
-----------------
NAVITAS and ENVISION: A Study to Characterize the Relationship Between Select Objective Metrics and Clinical Outcomes in Chronic Pain Patients Treated With Boston Scientific Neurostimulation Systems

Conditions
-----------------
Pain, Chronic

Intervention / Treatment
-----------------
* Device: Neurostimulation System


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: - Is willing and able to comply with completing protocol required assessments and evaluations Key Exclusion Criteria: - Has any pain-related diagnosis, medical/psychological condition or external factors that, in the investigator's medical judgment, might confound reporting of study outcomes (e.g. history of pelvic pain, anginal pain, chronic migraine, involved in litigation, workmen's compensation)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: De Novo Cohort<br>Study subjects who have not previously attempted a Neurostimulator trial will be followed up to 36 months post-Neurostimulation trial procedure or IPG Activation on the use of their Neurostimulation system. | Device: Neurostimulation System<br>* Spinal cord stimulation<br>|
| Active Comparator: Existing Cohort<br>Study subjects who have completed permanent neurostimulator IPG implant and are in various stages of follow-up will be followed up to 36 months post-Neurostimulation trial or IPG Activation procedure on the use of their Neurostimulation system. | Device: Neurostimulation System<br>* Spinal cord stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Intensity | Mean difference in pain intensity between Baseline and 6 months post neurostimulation trial visit (pain intensity assessed using 0-10 numerical rating scale) | 6 months |
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate the effects of androgen suppression with leuprolide and androgen replacement with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor neuron disease.

Detailed Description
-----------------
PROTOCOL OUTLINE: All patients receive androgen suppression with leuprolide acetate injections every 4 weeks for 6 months, plus hormone replacement therapy with testosterone enanthate injections every week for 24 weeks.

Conditions
-----------------
Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, Spinobulbar Muscular Atrophy

Intervention / Treatment
-----------------
* Drug: leuprolide
* Drug: testosterone


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Men aged 18 and over with motor neuron disease, i.e.: X-linked spinal and bulbar muscular atrophy (Kennedy's disease) Confirmed by androgen receptor, exon-1 mutation genotype Amyotrophic lateral sclerosis Spinal muscular atrophy Significant muscle weakness on manual muscle testing No prisoners No mental disability

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: leuprolide|nan|
|Drug: testosterone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
amyotrophic lateral sclerosis, motor neuron disease, neurologic and psychiatric disorders, rare disease, spinal and bulbar muscular atrophy, spinal muscular atrophy, Kennedy's Syndrome
Passive Mobilisation of Region of Shoulder Joints for Hemiplegic Patient

Study Overview
=================
Brief Summary
-----------------
Hemiplegia is a high prevalence pathology with 1 per 1000 habitants in France. One of these complications is shoulder pain which affects about 35 to 70% of cases. The medical care of this complication is critical because it affects the patient's quality of life and also hinders participation in rehabilitation sessions slowing the recovery of independence in activities of daily living. Literature confirmed the involvement of the scapula in the hemiplegic shoulder pain with his attitude pronounced lateral rotation. But no data to confirm that passive mobilization reduce shoulder pain. Because no data available to permit us to determine the sample size we set-up this preliminary study to check if efficiency found in these preliminary data are consistent with an estimable real efficacy in a randomized trial feasible.

Official Title
-----------------
Measurement of the Analgesic Efficacy of Shoulder Mobilization in Hemiplegic Patients

Conditions
-----------------
Hemiplegia

Intervention / Treatment
-----------------
* Procedure: Shoulder mobilisation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized in Physical Medicine and Rehabilitation at Centre Hospitalier Universitaire Réunion (Site of Le Tampon) Having made a cerebrovascular accident between 30 and 3 days before inclusion with pain in the upper limb whose score with visual analogue scale is greater than or equal to 20 mm able to understand the question: Do you have arm pain? Exclusion Criteria: with visual analogue scale score lower than 20 mm at the inclusion with aphasia of comprehension with medical contraindication for passive shoulder mobilisation (Shoulder fracture, dislocation,...) opposing to any mobilization with shoulder pathology previously known history of cerebrovascular accident prior 30 days before inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Shoulder mobilisation<br>The shoulder mobilisation is performed daily by a physiotherapist for 45 days. | Procedure: Shoulder mobilisation<br>* early shoulder mobilisation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain evaluation with visual analogic scale | Proportion of patients reducing by at least 20 mm their score on the visual analogic scale (VAS) from baseline Day 45 | Change of pain evaluation between Day 0 and Day 45 |
High-Risk Factors in Patients With Colorectal Polyps a Prospective Case-Control Study

Study Overview
=================
Brief Summary
-----------------
This prospective case-control study aimed to analyze and summarize the high-risk factors and susceptible genes of patients with colorectal polyps. According to these high-risk factors, the investigators developed and validated a prediction model for colorectal polyps to identify high-risk individuals, in order to provide clinical basis for the etiology research and the establishment of effective preventive measures.

Detailed Description
-----------------
A large cohort of eligible participants were included in the analysis, and classified into derivation and validation cohorts at a ratio of 7:3. Demographic and clinicopathological characteristics of participants were utilized to develop a prediction model for colorectal polyps. In the derivation cohort, the LASSO regression method was applied to filter variables and select the most useful high-risk factors. Multivariate logistic regression analysis was used to identify potential predictors and then a prediction model was established. The predictive performance of the model was evaluated with respect to its discrimination, calibration and clinical usefulness.

Official Title
-----------------
High-Risk Factors in Patients With Colorectal Polyps a Prospective Case-Control Study

Conditions
-----------------
Colorectal Polyp

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject aged ≥18 and ≤80 years old. Subject with complete data on demography and clinicopathology. Exclusion Criteria: - Subject with inflammatory bowel disease, enterophthisis, familial adenomatous polyposis, P-J syndrome and intestinal lymphoma. A history of severe systemic diseases: liver cirrhosis, metabolic syndrome, chronic kidney disease, malignancy. Subject taking blood lipid-lowering drugs, hormone or immunosuppressive agents. Unwillingness to cooperate with questionnaire survey. Lack of complete clinical data for analysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experimental group<br>patients with colorectal polyps | |
| control group<br>patients without intestinal diseases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic and clinicopathological characteristics of participants with polyps | demographic and clinicopathological characteristics | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Independent high-risk factors of participants with polyps | high-risk factors | 1 year |